National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No 2) (No PB 19 of 2013) [F2013L00575]; National Health (Pharmaceutical Benefits-Therapeutic Groups) Amendment Determination 2013 (No 1) (No PB 6 of 2013) [F2013L00573]; and National Health (Pharmaceutical Benefits-Therapeutic Groups) Amendment Determination 2013 (No 2) (No PB 7 of 2013) [F2013L00576]-New and continuing matters [2013] AUSStaCSDLM 170 (16 May 2013)

• National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2) (No. PB 19 of 2013) [F2013L00575]; National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 1) (No. PB 6 of 2013) [F2013L00573]; and National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 2) (No. PB 7 of 2013) [F2013L00576]

---

National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2) (No. PB 19 of 2013) [F2013L00575]; National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 1) (No. PB 6 of 2013) [F2013L00573]; and National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 2) (No. PB 7 of 2013) [F2013L00576]

Purpose	(1) Amends the National Health (Listed drugs on F1 or F2) Determination 2010 (No. PB 93 of 2010) to add three new listed drugs and to move other drugs between the F1, F2 and combination drug lists; (2) Amends the National Health (Pharmaceutical Benefits - Therapeutic Groups) Determination 2010 (No. PB 1 of 2010) to determine the Venlafaxine group and removes redundant definitions and other words; and (3) amends the National Health (Pharmaceutical Benefits - Therapeutic Groups) Determination 2010 (No. PB 1 of 2010) to remove certain drugs from the H2 receptor antagonist group
Last day to disallow	27 August 2013
Authorising legislation	National Health Act 1953
Department	Health and Ageing